1 July 2025 - Approximately 31,000 people with cystic fibrosis in the EU are now eligible for this new highly effective modulator therapy.
Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator gene.